Neuromyelitis Optica Clinical Trial
Official title:
Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica
Neuromyelitis Optica (NMO) is a demyelinating and degenerative disorder of the CNS affecting vision and spinal cord function. This disease is rare compared to Multiple Sclerosis (MS), but it is devastating and often leads to accumulating disability with a 5 year-mortality of approximately 30%. Survivors are typically left with severe morbidity secondary to blindness, quadriparesis and respiratory failure. No agent has been found to be highly effective in halting disease activity. Based on recent outcomes of stem cell transplant trials and reports in autoimmune diseases including MS, and based on the mechanisms of NMO, we anticipate that stem cell transplantation may provide lasting disease stability for NMO patients. The hypothesis of the present trial is that autologous hematopoetic stem cell transplantation in patients with NMO will provide lasting benefit in relapse prevention. Specifically, we anticipate a 50% reduction in the proportion of patients experiencing relapse over a three year period. We will be following patients for a total of five years after transplantation.
Patients who are deemed eligible will be enrolled and undergo a two stage transplant process followed by neurological assessments every 6 months for the following 5 years assessing EDSS, visual metrics, MRI, AQP-4 antibodies, MSFC and SF36. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02283671 -
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
|
Phase 1 | |
| Recruiting |
NCT01024985 -
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
|
N/A | |
| Recruiting |
NCT04601142 -
Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
|
||
| Completed |
NCT03942952 -
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
|
||
| Recruiting |
NCT05573711 -
Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
|
||
| Not yet recruiting |
NCT06118398 -
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05566769 -
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
|
N/A | |
| Withdrawn |
NCT03829566 -
Autologous Transplant To End NMO Spectrum Disorder
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT03350633 -
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05356858 -
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
|
Phase 2 | |
| Recruiting |
NCT05982925 -
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
|
||
| Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
| Terminated |
NCT02398994 -
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
|
Phase 3 | |
| Withdrawn |
NCT02087813 -
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
|
Phase 1 | |
| Recruiting |
NCT02021825 -
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
|
Phase 4 | |
| Active, not recruiting |
NCT04614454 -
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
|
Phase 2 | |
| Recruiting |
NCT03370965 -
Optic Neuritis Differential Diagnosis Study
|
N/A | |
| Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
| Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|